Comparative Pharmacology
Head-to-head clinical analysis: MEZLIN versus PFIZERPEN AS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEZLIN versus PFIZERPEN AS.
MEZLIN vs PFIZERPEN-AS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mezlocillin is a ureidopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
PFIZERPEN-AS (penicillin G procaine) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and transglycosylation, leading to cell lysis.
3-4 g intravenously every 4-6 hours; maximum 24 g/day.
250-500 mg orally every 6-8 hours for moderate infections; 500 mg to 2 g intravenously every 4-6 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life is 0.7-1.2 hours in healthy adults; prolonged to 2-5 hours in renal impairment (CrCl <20 mL/min) and up to 10-20 hours in ESRD.
0.5-1 hour in healthy adults; prolonged to 2.5-10 hours in renal impairment (CrCl <10 mL/min). Clinically relevant for dosing interval adjustment in renal dysfunction.
Renal (70-80% unchanged via glomerular filtration and tubular secretion); biliary (approximately 2-3%); fecal (minor).
Primarily renal (60-80% as unchanged drug via tubular secretion and glomerular filtration); minor biliary/fecal elimination (10-20%)
Category C
Category C
Antibiotic (Penicillin)
Antibiotic (Penicillin)